眼科首诊的癌症相关性视网膜病变1例  

Cancer-associated retinopathy first diagnosed in ophthalmology:a case report

作　　者：刘元媛 徐敏 朱俊 陈放 Liu Yuanyuan;Xu Min;Zhu Jun;Chen Fang(Department of Ophthalmology,Northern Jiangsu People′s hospital,Yangzhou,225001,China)

机构地区：[1]苏北人民医院眼科,扬州225001

出　　处：《中华转移性肿瘤杂志》2024年第5期510-513,共4页Chinese Journal of Metastatic Cancer

摘　　要：1例主诉为"双眼无痛性视力下降1月余"患者首诊于眼科,患者血清及右眼房水抗恢复蛋白抗体结果均为阳性,支气管镜检查病理结果示小细胞癌,最终诊断为双眼癌症相关性视网膜病变、小细胞肺癌。2021—2022年该患者行6次EP化疗(依托卡铂1.5 g第1~3天+顺铂60 mg第1~2天),肿瘤原发灶有所缩小,但双眼视力无好转;后患者继续于呼吸科随访至2024年7月,行3次EP方案化疗联合免疫检查点抑制剂治疗(依托卡铂1.0 g第1~3天+顺铂30 mg第1~3天+特瑞普利单抗240 mg第1天),目前患者仍在随访中。A patient complained of painless visual acuity loss in both eyes for more than a month.Anti-recoverin antibody was detected positively in the patient's serum and aqueous humor of the right eye.Small cell lung carcinoma was diagnosed by bronchoscopy and the pathological examination.The final diagnosis was bilateral cancer-associated retinopathy and small cell lung carcinoma.From 2021 to 2022,the patient was treated with EP chemotherapy for six times(etocarboplatin 1.5 g d1-3+cisplatin 60 mg d1-2).The primary tumor shrunk,but the visual acuity in both eyes was not improved.After that,the patient continued to be followed up in the respiratory department until July 2024,and underwent three EP regimens of chemotherapy combined with PD-1 inhibitor immunotherapy(etocarboplatin 1.0 g d1-3+cisplatin 30 mg d1-3+toripalimab 240 mg d1).The patient is still being followed up now.

关 键 词：副肿瘤综合征 癌症相关性视网膜病变 抗恢复蛋白抗体 

分 类 号：R730.6[医药卫生—肿瘤] R774.1[医药卫生—临床医学]